59749-22-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-chlorobenzyl)-5-oxo-L-proline is used as an intermediate in the synthesis of complex organic molecules and potential drug candidates. Its unique structure and properties make it a promising compound for drug discovery and development, contributing to the advancement of novel therapeutics.
Used in Agricultural Products:
1-(4-chlorobenzyl)-5-oxo-L-proline is used as a building block in the production of new materials and chemicals for the agricultural industry. Its unique properties allow for the creation of innovative products that can enhance agricultural practices and improve crop yields.
Used in Research:
1-(4-chlorobenzyl)-5-oxo-L-proline serves as a valuable compound in scientific research, particularly in the fields of organic chemistry and biochemistry. Its unique structure and properties make it an interesting subject for studying various chemical reactions and biological processes, furthering our understanding of complex molecular interactions.

Upstream product

• 622-95-7 4-chlorobenzyl bromide 
• 98-79-3 L-Pyroglutamic acid 
• 4931-66-2 methyl (S)-pyroglutamate 
• 59749-18-7 (S)-1-(4-Chloro-benzyl)-5-oxo-pyrrolidine-2-carboxylic acid methyl ester 

Downstream Products

• 1615249-84-7 tert-butyl ((R)-1-((S)-1-(4-chlorobenzyl)-5-oxopyrrolidine-2-carbonyl) piperidin-3-yl)methylcarbamate 
• 1615249-83-6 tert-butyl ((S)-1-((S)-1-(4-chlorobenzyl)-5-oxopyrrolidine-2-carbonyl) piperidin-3-yl)methylcarbamate 

Relevant academic research and scientific papers

Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation

A series of chiral lactam carboxamides of aminomethylpiperidine were synthesized and investigated for the collagen induced in vitro anti-platelet efficacy and collagen plus epinephrine induced in vivo pulmonary thromboembolism. The compound 31a (30 μM/kg) displayed a remarkable antithrombotic efficacy (60% protection) which was sustained for more than 24 h and points to its excellent bioavailability. The compounds 31a (IC50 = 6.6 μM) and 32a (IC50 = 37 μM), as well as their racemic mixture 28i (IC50 = 16 μM) significantly inhibited collagen-induced human platelet aggregation in vitro. Compound 34c displayed dual mechanism of action against both collagen (IC50 = 3.3 μM) and U46619 (IC50 = 2.7 μM) induced platelet aggregation. The pharmacokinetic study of 31a indicated very faster absorption, prolonged and constant systemic exposure and thereby exhibiting better therapeutic response.

In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors

Among matrix metalloproteinases (MMPs), gelatinases MMP-2 (gelatinase A) and MMP-9 (gelatinase B) play a key role in a number of physiological processes such as tissue repair and fibrosis. Many evidences point out their involvement in a series of patholog

Protection by pyroglutamic acid and some of its newly synthesized derivatives against glutamate-induced seizures in mice

The protection by pyroglutamic acid (CAS 98-79-3) and derivatives Ia-i (injected i.p.) against glutamate- and NMDA (N-methyl-D-aspartate) (i.c.v.) induced seizures in mice has been studied in comparison with known antiepileptics and antagonists of excitatory aminoacids. The potency of pyroglutamic acid and some derivatives (Id,f,g,h) against glutamate-induced convulsions was similar to that shown by glutamic acid diethylester and by valproic acid. Interestingly, pyroglutamic acid did not affect NMDA-induced convulsions which were well antagonized by both 2-amino-5-phosphono valeric acid and by diazepam. Thus, pyroglutamic acid may represent the starting for synthesis of excitatory aminoacid antagonists acting at non NMDA receptors.